🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The WHO Classification of Tumours — the “blue books” — can do better. Of 61 expert members across 3 major volumes (digestive, breast, female genital), only 2 are from the Global South — where 85% of the world’s population lives. Is IARC blind to the Global South?

I agree —but I also expect more from the World Health Organization. To me, this isn’t just an oversight. It feels anti-diversity, anti-equity, and anti-inclusion. I am particularly shocked by the complete lack of representation from the Global South in the Female Genital Tumours

📊 The Area Under the Curve (AUC) is a single number that shows how well a model can tell categories apart. It combines sensitivity (finding true positives) and specificity (avoiding false positives) into one overall score. A perfect model has an AUC of 1.0—no missed diagnoses,

Sox17! Fantastic review. Congratulations Avash Das, MBBS, PhD

Microsoft’s Healthcare Agent Orchestrator unites specialised AI agents—radiology, pathology, trials, guidelines, staging, and patient history—to support faster cancer diagnoses

Dr. Veronica Alvarez presentating at NESP!

Without its international students, Harvard is not Harvard. hrvd.me/IntStudents25t

What is the primary role of the WHO Tumour Classification (“blue books”)? 1️⃣ To catalogue all known tumour entities with scientific precision 2️⃣ To provide a practical, inclusive, globally applicable diagnostic framework, including the Global South 3️⃣ Both (although not

Reviewing the composition of the 6th edition WHO Tumour Classification expert panels for breast, female genital, and digestive system tumours, I found that only 5.4% of the experts are from low- and middle-income countries (LMICs). The remaining 94.6% hail from high-income

Thanks again, Mette. I can’t help but draw a comparison between the WHO Blue Books and the WHO Model List of Essential Medicines (EML) [🔗 who.int/publications/i…] and the Essential Diagnostics List (EDL) [🔗 who.int/publications/m…]. That might be the starting point of the

This feasibility study, conducted by Quest Diagnostics, evaluated Proscia’s Concentriq digital pathology platform, integrated with Ibex’s Galen Prostate AI tool. While not yet peer-reviewed, these initial results could significantly influence diagnostic workflows in the US,

Can’t stop progress, but we need solutions for the environmental impact.

More proof why WHO tumour classifications fail in low- and middle-income countries: 👉Essential IHC is available in only 12.5% of low-income countries. 👉Molecular diagnostics are accessible to 0% of low-income countries. 👉Based on a survey of pathologists from 76 countries.

Does not have to be all or nothing. One option would be to only digitise biopsies (smaller digital footprint) but not resections. Have to consider the costs (not just monetary) and the potential benefits.